Drug intelligence / Profile preview

AG-920

Development stage: Unknown
Lead developer: American Genomics
Modality: Small Molecules
Administration: Ophthalmic

Overview

AG-920 is a novel topical ocular anesthetic containing 8% articaine in a sterile ophthalmic solution. It is designed to provide local anesthesia for ophthalmic procedures. The drug has been evaluated for both safety and efficacy in adults and pediatric patients. AG-920 is administered as eye drops, with a typical dose consisting of two drops in the study eye.

Brand names: Cyklx
Other names: Articaine Sterile Topical Ophthalmic Solution

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on AG-920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-920.